Hyperuricemia reduces the risk of MCI but not dementia: a cross-sectional study in Liuyang

Cognitive impairments, including mild cognitive impairment (MCI) and dementia, significantly affect patients' daily functions and quality of life, contributing to a substantial societal and economic burden. The role of uric acid in cognitive function is controversial, with some studies suggesting protective effects, while others indicate increased risk of cognitive decline.

A total of 1,098 participants with an average age of 69 years were included in the study. Cognitive function was assessed using the Mini-Mental State Examination. Hyperuricemia was defined as blood uric acid concentrations >420 μmol/L. Logistic regression and restricted cubic spline analysis were performed to assess the association between hyperuricemia and cognitive impairment, including MCI and dementia.

Hyperuricemia was associated with a lower risk of cognitive impairment (OR = 0.51, 95% CI = 0.31-0.80) and MCI (OR = 0.39, 95% CI = 0.21-0.69), particularly in individuals younger than 70 years, males, and those without hypertension or diabetes. No significant association was found between hyperuricemia and dementia (OR = 0.94, 95% CI = 0.44-1.89). There is no evidence of a non-linear relationship between hyperuricemia and cognitive impairment.

Hyperuricemia appears to have a protective effect on cognitive function, particularly in reducing the risk of MCI, but not dementia, in specific populations.